Compared with postoperative stereotactic radiation therapy, an investigational intraoperative RT approach could significantly reduce local tumor recurrence and improve survival in patients with newly diagnosed operable brain metastases.
The new device, designed to perform mitral valve repair in patients with functional MR, was co-invented by cardiologist Samir Kapadia, MD, and surgeon Jose Navia, MD.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
